Figure 1. Model structure
Strategy A: Oncomine DxTT
Strategy B: Three single-gene tests (EGFR/ALK/ROS1)
Strategy C: One single-gene test (EGFR)
Strategy D: No genetic testing
NSCLC, non-small cell lung cancer; PS, performance status; pT+, proportion of positive test (pTP + pFP); pT−, proportion of negative test (pTN + pFN); pTP, true-positive probability; pFP, false-positive probability; pTN, true-negative probability; pFN, false-negative probability; CDDP, cisplatin; PEM, pemetrexed.
From: Cost-effectiveness Analysis of the Oncomine™ Dx Target Test MultiCDx System Using Next-generation Sequencing and Single-gene Test in Advanced and Recurrent Nonsquamous Non-small-cell Lung Cancer
